Rates Party Like It’s 2007 ⚡

Welcome to LazyListen. This is The Daily Rip for today. S.

stocks slipped on Tuesday as investors remained cautious amid persistent inflation concerns and rising bond yields. The July Consumer Price Index report from last week continues to cast a shadow over market sentiment, with longer-term Treasury yields climbing to levels not seen since 2007. This surge in yields is signaling that bond markets expect higher interest rates and ongoing inflation pressures ahead, keeping traders on edge.

To set the stage, the 30-year Treasury yield surged sharply this week, reaching its highest point in over 15 years. The 10-year Treasury yield is now about a full percentage point above the Federal Reserve’s current target rate. This gap suggests that bond investors—sometimes called “bond vigilantes”—are pricing in a more aggressive rate environment than the Fed’s official stance, reflecting concerns about persistent inflation and potential economic turbulence.

Justin Onuekwusi, Chief Investment Officer at St. James Place, told Bloomberg that the market is bracing for turmoil and continued inflation risks, a sentiment echoed across global fixed income markets as other long-dated government bonds followed suit. Against this backdrop, tech stocks led the market decline on Tuesday, dragging the broader indices lower.

The semiconductor sector was hit particularly hard, with major chipmakers like Micron and Intel falling sharply. Micron’s shares dropped about seven percent, while Intel’s stock fell nearly seven percent as well. These declines reflect investor worries about weakening demand and margin pressures in the semiconductor industry, which is often seen as a bellwether for global technology spending and supply chain health.

While tech and chips struggled, some pockets of strength emerged elsewhere. Defensive sectors, especially healthcare, held up better amid the volatility. Blue-chip healthcare giants Eli Lilly and Johnson & Johnson both gained more than three percent, highlighting a classic flight to safety as investors sought stability in uncertain times.

These gains underscore the ongoing appeal of healthcare stocks as a defensive hedge when growth sectors face headwinds. This week also marks the start of retail earnings season, with investors closely watching how consumer spending is holding up amid inflationary pressures and economic uncertainty. Home Depot reported solid quarterly results on Tuesday morning, beating earnings per share estimates by around four percent.

However, the stock edged down slightly after the report, indicating that investors remain cautious about the sustainability of consumer demand. Despite the beat, concerns linger about how inflation and higher interest rates might impact discretionary spending in the months ahead. In the biotech sector, Amylyx Pharmaceuticals stole the spotlight after the market closed.

The clinical-stage biotech announced positive Phase 3 trial results for its drug avexitide, which reduced serious low-blood-sugar events by fifty-five percent. This significant clinical win clears the way for Amylyx to file an FDA application by year-end, a major milestone for the company. Shares soared more than sixty percent in after-hours trading, reflecting strong investor enthusiasm.

To capitalize on this momentum, Amylyx also proposed a 350 million dollars stock offering to fund pre-commercial activities and further research and development. While this raises dilution concerns, investors appear willing to reward the company for hitting all its clinical endpoints and advancing toward a potential 2027 product launch. Amylyx’s cash position stood at about 250 million dollars as of June 30, so the additional capital will support scaling up operations ahead of regulatory approval.

Elsewhere in fintech, Klarna reported an earnings beat but issued weaker guidance, resulting in a steep twenty three percent selloff. The company’s outlook raised concerns about growth prospects amid a challenging consumer credit environment, highlighting the ongoing headwinds facing buy-now-pay-later and other fintech platforms as consumers tighten their wallets. Turning to other notable movers, EyePoint Pharmaceuticals rebounded fourteen percent after a recent setback in its Phase 3 trial.

Investors remain hopeful about upcoming data that could revive the company’s prospects, although regulatory approval still remains uncertain. This rebound reflects cautious optimism in the biotech space, where trial results can dramatically shift sentiment. Retailer Target edged up one percent ahead of its quarterly report due Wednesday.

Shares have already climbed more than fifty percent this year as investors have embraced the company’s turnaround efforts. However, the market will be watching closely to see if Target can sustain momentum amid ongoing consumer uncertainty and a reset in its beauty segment, which has been a key growth driver. I.

infrastructure names faced pressure from rising Treasury yields. TeraWulf’s stock dropped eleven percent despite a recent deal announcement, as investors questioned whether growth expectations are already priced in. Similarly, WhiteFiber plunged thirty-two percent after announcing a 250 million dollars convertible note offering to fund data center expansion in North Carolina.

The financing move raised dilution concerns just as the company ramps up capacity, prompting a selloff amid worries about valuation and capital structure. Looking ahead, the market’s attention turns to the Federal Reserve’s upcoming meeting minutes, scheduled for release at 2 PM Eastern tomorrow. Investors will be parsing the details for clues on the Fed’s next moves as it balances persistent inflation against signs of economic slowing.

The minutes could provide important insight into whether the Fed plans to continue raising rates or begin to signal a pause. Earnings will also remain in focus, with major retailers like Target and Lowe’s reporting before the open Wednesday. After the bell, investors will digest results from companies including Wolfspeed, Coty, and Webull.

These reports will help shape expectations for consumer spending and corporate profitability as the third quarter unfolds. In summary, the market remains caught between stubborn inflation signals and cautious optimism from pockets of earnings strength. Rising bond yields are challenging growth sectors, particularly tech and capital-heavy infrastructure names, while defensive healthcare stocks provide some stability.

Biotech’s headline-grabbing trial wins offer excitement but come with typical risks around funding and regulatory approval. Tomorrow’s Fed minutes and retail earnings will be key to setting the tone for the rest of the week. Thanks for listening.

Catch you next time on LazyListen.